AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)

Posoleucel demonstrated clinically meaningful reductions in BK viral load as compared to placebo with the greatest antiviral activity seen among patients with higher viral loads and those who... | June 5, 2023

Related Keywords

United States ,San Diego ,California ,American ,Diana Brainard ,European Medicines Agency ,Allovir Inc ,Nasdaq ,Drug Administration ,American Transplant Congress ,Kidney Transplant ,Regenerative Medicine Advanced Therapy ,Orphan Drug Designation ,Orphan Medicinal Product ,Private Securities Litigation Reform Act ,American Society ,Transplantation Infectious Diseases Community ,Allovir ,Nc Stock Exchange ,News ,Information ,Press Release ,Osoleucel ,Remonstrated ,Linically ,Meaningful ,Reductions ,N ,Uk ,Viral ,Road ,Us ,Ompared ,O ,Placebo ,Ith ,The ,Greatest ,Antiviral ,Activity ,Teen ,Mong ,Patients ,Higher ,Roads ,End ,Hose Alvr Us0198181036 ,